59th Annual Meeting of the Japanese Society of Neurology
May 23 - May 26, 2018Royton Sapporo/Nitori Culture Hall and Hotel Sapporo Geibunkan/Sapporo Education and Culture Hall
59th Annual Meeting of the Japanese Society of Neurology
May 23 - May 26, 2018Royton Sapporo/Nitori Culture Hall and Hotel Sapporo Geibunkan/Sapporo Education and Culture Hall
[HT-02-4]A first Antisense Oligonucleotide (ASO) therapy, Nusinersen, for Spinal Muscular Atrophy
○Shinichi Torii(Biogen Japan Ltd., Japan)
March, 1984 Graduated from Gifu College of Pharmacy
March, 2002 Ph.D degree from Molecular Biology from Tokyo University, Graduate School
April, 1984～ Janssen Pharmaceutical K.K.
April, 2007～ Celgene Corporation
April, 2010～ Olympus Corporation
January, 2011～ Chief Scientific Officer (CSO), Olympus Biotech Corporation (Boston, USA)
June, 2014～ Head of R&D, Biogen Japan Inc.
April, 2017～ President & Representative Director, Biogen Japan Inc.
March, 2002 Ph.D degree from Molecular Biology from Tokyo University, Graduate School
April, 1984～ Janssen Pharmaceutical K.K.
April, 2007～ Celgene Corporation
April, 2010～ Olympus Corporation
January, 2011～ Chief Scientific Officer (CSO), Olympus Biotech Corporation (Boston, USA)
June, 2014～ Head of R&D, Biogen Japan Inc.
April, 2017～ President & Representative Director, Biogen Japan Inc.
Password required to view
Abstract password authentication.
Password is written on a pocket program and name badge.
Password is written on a pocket program and name badge.